LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?

    Onuma, Yosinobu / Serruys, Patrick W

    Circulation

    2011  Volume 123, Issue 7, Page(s) 779–797

    MeSH term(s) Angioplasty, Balloon, Coronary/instrumentation ; Angioplasty, Balloon, Coronary/trends ; Animals ; Cardiology/trends ; Coronary Artery Disease/therapy ; Humans ; Polymers ; Stents/trends ; Tissue Scaffolds/trends
    Chemical Substances Polymers
    Language English
    Publishing date 2011-02-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80099-5
    ISSN 1524-4539 ; 0009-7322 ; 0069-4193 ; 0065-8499
    ISSN (online) 1524-4539
    ISSN 0009-7322 ; 0069-4193 ; 0065-8499
    DOI 10.1161/CIRCULATIONAHA.110.971606
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui IV Zs.60: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Bioresorbable scaffold technologies.

    Onuma, Yosinobu / Ormiston, John / Serruys, Patrick W

    Circulation journal : official journal of the Japanese Circulation Society

    2011  Volume 75, Issue 3, Page(s) 509–520

    Abstract: Fully bioabsorbable scaffolds (BRS) are a novel approach that provides transient vessel support with drug delivery capability without the long-term limitations of the metallic drug-eluting stents (DES), such as permanent caging with or without ... ...

    Abstract Fully bioabsorbable scaffolds (BRS) are a novel approach that provides transient vessel support with drug delivery capability without the long-term limitations of the metallic drug-eluting stents (DES), such as permanent caging with or without malapposition. The technology has the potential to overcome many of the safety concerns associated with metallic DES, and possibly even convey further clinical benefit. Although the technology is still in its infancy, several devices have been tested in clinical trials and the initial results have been very promising. This review will discuss the emerging need for BRS, the theoretical advantages of this new technology over current generation metallic DES and review the status of the currently available BRS. In addition, we will discuss the ideal duration of bioresorption, the proven and potential clinical benefits and future perspectives of this rapidly progressing technology.
    MeSH term(s) Absorbable Implants/trends ; Angioplasty, Balloon, Coronary/methods ; Biotechnology/methods ; Biotechnology/trends ; Coronary Restenosis/prevention & control ; Coronary Stenosis/therapy ; Drug-Eluting Stents/adverse effects ; Humans ; Tissue Scaffolds/trends
    Language English
    Publishing date 2011-02-03
    Publishing country Japan
    Document type Journal Article ; Review
    ZDB-ID 2068090-9
    ISSN 1347-4820 ; 1346-9843
    ISSN (online) 1347-4820
    ISSN 1346-9843
    DOI 10.1253/circj.cj-10-1135
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui IV Zs.74: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial.

    Onuma, Yosinobu / Serruys, Patrick W / Ormiston, John A / Regar, Evelyn / Webster, Mark / Thuesen, Leif / Dudek, Dariusz / Veldhof, Susan / Rapoza, Richard

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

    2010  Volume 6, Issue 4, Page(s) 447–453

    Abstract: Aims: Multimodality imaging of the first-in-man trial using a fully resorbable everolimus-eluting scaffold (BVS, Abbott Vascular, Santa Clara, CA, USA) demonstrated at two years the bioresorption of the device while preventing restenosis. Nevertheless, ... ...

    Abstract Aims: Multimodality imaging of the first-in-man trial using a fully resorbable everolimus-eluting scaffold (BVS, Abbott Vascular, Santa Clara, CA, USA) demonstrated at two years the bioresorption of the device while preventing restenosis. Nevertheless, the long-term safety and efficacy of this novel therapy remain to be documented.
    Methods and results: The ABSORB trial completed in July 2006 at four clinical sites in Europe and New Zealand the enrolment of 30 patients with a single de novo native coronary artery lesion. The major clinical endpoint was ischaemia-driven major adverse cardiac events (ID-MACE) defined as a composite of cardiac death, myocardial infarction, or ischaemia-driven target lesion revascularisation. Clinical follow-up was available in 29 patients since one patient withdrew consent. At 46 days, one patient experienced a single episode of chest pain and underwent a diagnostic optical coherence tomography and subsequently a target lesion revascularisation with slight troponin rise after the procedure. At 3-year the hierarchical ID-MACE of 3.4% remained unchanged. Clopidogrel therapy was discontinued in all but one patient. There has been no stent thrombosis reported. Two non-cardiac deaths were reported; one from duodenal perforation, the other from Hodgkin disease. Two patients underwent non-ischaemia driven target vessel revascularisation.
    Conclusions: Three-year clinical results have demonstrated a sustained low MACE rate (3.4%) without any late complication such as stent thrombosis.
    MeSH term(s) Absorbable Implants ; Aged ; Angioplasty, Balloon, Coronary/adverse effects ; Angioplasty, Balloon, Coronary/instrumentation ; Angioplasty, Balloon, Coronary/methods ; Coronary Artery Disease/therapy ; Drug-Eluting Stents/adverse effects ; Everolimus ; Female ; Follow-Up Studies ; Humans ; Immunosuppressive Agents/administration & dosage ; Male ; Middle Aged ; Sirolimus/administration & dosage ; Sirolimus/analogs & derivatives
    Chemical Substances Immunosuppressive Agents ; Everolimus (9HW64Q8G6G) ; Sirolimus (W36ZG6FT64)
    Language English
    Publishing date 2010-09
    Publishing country France
    Document type Clinical Trial ; Journal Article
    ZDB-ID 2457174-X
    ISSN 1969-6213 ; 1774-024X
    ISSN (online) 1969-6213
    ISSN 1774-024X
    DOI 10.4244/EIJ30V6I4A76
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6680: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 571: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top